UK Regulator Strengthens GLP-1 Pancreatitis Warning
UK regulator MHRA updated safety labels for all GLP-1s after post-marketing reports of fatal and necrotising pancreatitis in a small number of cases.
May 18, 2026 · 3 min read
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a Drug Safety Update on January 29, 2026, updating product information for all GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists to strengthen warnings around acute pancreatitis, including rare but severe reports of necrotising and fatal cases. The affected drugs include dulaglutide, exenatide, liraglutide, semaglutide, and tirzepatide.
What Happened
The MHRA's update followed review of Yellow Card post-marketing safety reports accumulated over 18 years of GLP-1 use. Between 2007 and October 2025, the agency received 1,296 Yellow Card reports of pancreatitis associated with GLP-1 or dual GLP-1/GIP receptor agonists. Of those:
- 19 reports involved a fatal outcome
- 24 reports involved necrotising pancreatitis
- For semaglutide specifically: 256 cases reported between 2019 and 2025, with 4 fatal outcomes
The MHRA concluded that while pancreatitis remains an infrequent event, post-marketing data showed that a small subset of reported cases involved outcomes significantly more severe than what early clinical trials captured.
Product information across all affected drugs has been updated to explicitly highlight the potential for severe pancreatitis, not just mild or moderate cases.
Why It Matters
The updated warning doesn't change the overall benefit-risk assessment for GLP-1 drugs, which remain approved for their indications. What it changes is the prominence of the pancreatitis signal in labeling — moving from a general "uncommon adverse effect" framing to one that acknowledges the rare but real possibility of severe outcomes.
For context: the background rate of acute pancreatitis in adults with obesity and type 2 diabetes — the primary populations on GLP-1 drugs — is already elevated compared to the general public. Disentangling drug-attributable pancreatitis from background disease risk is methodologically difficult, which is partly why this signal took years of post-marketing accumulation to prompt a label update.
The MHRA update also notes the mechanistic link between gallstones — which GLP-1s can promote through rapid weight loss and reduced gallbladder motility — and pancreatitis. Gallstone-induced pancreatitis is a known pathway, and elevated gallstone risk in GLP-1 users may contribute to the pancreatitis signal. See semaglutide and gallbladder risk for the gallstone mechanism specifically.
What to Watch
The MHRA warning applies to the UK market. The US FDA has not issued a comparable update at this time, though FDA labeling for GLP-1 drugs already lists pancreatitis as a known adverse event.
Healthcare professionals in the UK are advised to remain alert to symptoms: severe, persistent stomach pain that radiates to the back, accompanied by nausea and vomiting — and to discontinue GLP-1 therapy and evaluate promptly if pancreatitis is suspected. Patients should be counseled not to dismiss persistent upper abdominal pain as typical GI side effects.
For the broader side effect picture across GLP-1 drugs, including how to distinguish pancreatitis symptoms from the more common nausea and GI effects, see GLP-1 side effects overview and the pancreatitis cluster.
Sources
Sources